Travere Therapeutics (TVTX) Total Current Liabilities (2012 - 2026)

Travere Therapeutics has reported Total Current Liabilities for 15 years, with the latest figure at $125.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 31.25% year-over-year to $125.4 million; the trailing twelve-month figure through Mar 2026 stood at $125.4 million (down 31.25% YoY), and the FY2025 full-year result was $159.9 million, down 20.35% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $125.4 million, down from $159.9 million in the prior quarter.
• The five-year high for Total Current Liabilities was $200.8 million in Q4 2024, with the low at $119.5 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $151.7 million across 5 years, with a median of $139.4 million in 2023.
• Annual changes were most pronounced in 2025 — Total Current Liabilities jumped 56.3% — and 2026, when it slumped 31.25%.
• Travere Therapeutics' Total Current Liabilities stood at $142.2 million in 2022, then climbed by 25.14% to $177.9 million in 2023, then gained by 12.84% to $200.8 million in 2024, then dropped by 20.35% to $159.9 million in 2025, then dropped by 21.55% to $125.4 million in 2026.
• The last three Total Current Liabilities figures came in at $125.4 million (Q1 2026), $159.9 million (Q4 2025), and $135.1 million (Q3 2025), per Business Quant data.